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Introduction: The incidence of death among patients admitted for severe sepsis or septic shock is high.
Adrenomedullin (ADM) plays a central role in initiating the hyperdynamic response during the early stages of sepsis. Pilot
studies indicate an association of plasma ADM with the severity of the disease. In the present study we utilized a novel
sandwich immunoassay of bioactive plasma ADM in patients hospitalized with sepsis in order to assess the clinical utility.
Methods: We enrolled 101 consecutive patients admitted to the emergency department with suspected sepsis in this
study. Sepsis was defined by fulfillment of at least two systemic inflammatory response syndrome (SIRS) criteria plus
clinical suspicion of infection. Plasma samples for ADM measurement were obtained on admission and for the next four
days. The 28-day mortality rate was recorded.
Results: ADM at admission was associated with severity of disease (correlation with Acute Physiology and Chronic
Health Evaluation II (APACHE II) score: r = 0.46; P <0.0001). ADM was also associated with 28-day mortality (ADM median
(IQR): survivors: 50 (31 to 77) pg/mL; non-survivors: 84 (48 to 232) pg/mL; P <0.001) and was independent from and
additive to APACHE II (P = 0.02). Cox regression analysis revealed an additive value of serial measurement of ADM over
baseline assessment for prediction of 28-day mortality (P < 0.01). ADM was negatively correlated with mean arterial
pressure (r = −0.39; P <0.0001), and it strongly discriminated those patients requiring vasopressor therapy from the
others (ADM median (IQR): no vasopressors 48 (32 to 75) pg/mL; with vasopressors 129 (83 to 264) pg/mL, P <0.0001).
Conclusions: In patients admitted with sepsis, severe sepsis or septic shock plasma ADM is strongly associated with
severity of disease, vasopressor requirement and 28-day mortality.Introduction
The global incidence of severe sepsis is greater than of
either cancer or myocardial infarction, with a mortality
rate estimated at 40% [1-3]. This high mortality is in
many cases linked to multi-organ hypoperfusion and
hypotension associated with the development of septic
shock. As the clinical and laboratory findings of sepsis
are nonspecific and culture results are not readily available,
the diagnosis and risk stratification of patients is often
delayed [4]. Biomarkers such as C-reactive protein (CRP),
leukocyte count, lactate and Procalcitonin (PCT) are
often used to differentiate between systemic inflammatory
response syndrome (SIRS), sepsis, severe sepsis and septic
shock as well as for patient risk stratification [5-7].* Correspondence: salvatore.disomma@uniroma1.it
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unless otherwise stated.Adrenomedullin (ADM) is a peptide first isolated from
a human pheochromocytoma [8], and has been found to
be elevated in plasma of sepsis patients [9-11]. The
mechanism of secretion of ADM in large part relates to
the effects of lipopolysaccharide (LPS) stimulation [12].
Previous studies indicate that ADM plays a major role in
initiating the hyperdynamic response during the early
stages of polymicrobial sepsis [13,14]. Due to the cum-
bersome competitive immunoassays requiring extraction
of large sample volumes, thus far plasma ADM has been
determined only in a small number of sepsis patients
[9,15-17]. Therefore, the potential value of determining
plasma ADM in such patients cannot yet be ascertained.
Recently, a new double-monoclonal antibody sandwich
immunoassay for the measurement of human mature
ADM has been developed facilitating the reliable and sim-
ple assessment of this biomarker [18]. The assay selectivelyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
Variable Total population
(n = 101)
Demographics
Gender, male, n (%) 61 (60.4)
Age, years, median (IQR) 78 (72 to 83)
Examination variables
Respiratory rate, acts/minute, median (IQR) 24 (22 to 28)
Body temperature,°C, median (IQR) 38.4 (36 to 38.7)
Glasgow Coma Scale, points, median (IQR) 15 (10 to 15)
Mean arterial pressure, mm Hg, median (IQR) 83.3 (74 to 93)
Past medical history
Cardiovascular, yes, n (%) 26 (25.7)
Hypertensive, yes, n (%) 47 (46.5)
Diabetes, yes, n (%) 35 (34.7)
Cancer, yes, n (%) 13 (12.9)
Labaratory variables
ADM, pg/mL, median (IQR) 53.8 (37.4 to 94.0)
PCT, ng/mL, median (IQR) 2.8 (0.6 to 10.7)
Creatinine clearance, mL/minute, median (IQR) 48 (23 to 77)
Creatinine, mg/dL, median (IQR) 1.3 (0.9 to 2.4)
CRP, mg/dL, median (IQR) 16 (6.6 to 25.6)
White cells, 109 cells/L, median (IQR) 12.7 (6.8 to 17.6)
Platelets, 109 cells/L, median (IQR) 213 (150 to 278)
Other
Final diagnosis, severe sepsis/shock, n (%) 29 (28.7)
Length of stay, days, median (IQR) 5 (2 to 7)
Septic shock at arrival, yes, n (%) 25 (24.8)
Acute organ dysfunction, yes, n (%) 39 (38.6)
APACHE II score, points, median (IQR) 16 (13 to 21)
Treatment at baseline
Steroids, yes, n (%) 16 (15.8)
Vasopressors, yes, n (%) 18 (17.8)
Antibiotics, yes, n (%) 101 (100)
Fluid therapy, yes, n (%) 101 (100)
ADM, Adrenomedullin; PCT, Procalcitonin; CRP, C-reactive protein.
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contrast to the glycine-extended ADM variant is bioactive.
Our study aimed to explore the clinical utility of basal and
serial plasma ADM assessments in patients hospitalized for
sepsis using this new assay.
Materials and methods
Patient population
This was a prospective observational study performed in the
Emergency Department (ED) Sant’Andrea Hospital Univer-
sity La Sapienza Rome, from December 2011 to April 2012.
Patients presenting to the ED with suspected sepsis accord-
ing to the Surviving Sepsis Campaign guidelines [19] and
need for hospitalization were considered eligible for the
study. We enrolled 101 consecutives patients (61 males and
40 females) with median (IQR) age 78 (72 to 83) years. Nu-
merous comorbidities such as diabetes and hypertension
were present: 29% of the patients had severe sepsis or septic
shock on admission (Table 1).
All patients gave informed written consent according
to the Helsinki declaration. The study was approved by
the ethical committee of Sant’ Andrea Hospital in Rome.
Anamnestic data, physical examination, electrocardiogram,
routine laboratory test, and instrumental radiologic exami-
nations were performed for each patient. At arrival and for
the first 4 days after hospitalization all patients underwent
monitoring of vital parameters, including temperature,
physical examination, arterial blood analysis, and fluid
balance. The acute physiology and chronic health evalu-
ation II (APACHE II) score was calculated during the
first 24 hours after admission [20]. During hospitalization
therapy, physical examination, fluid balance, vital parame-
ters and culture examinations were recorded on a clinical
research form. Survival was recorded daily by in-hospital
observation and later by phone call, respectively, over a
period of 28 days after admission to the ED.
ADM measurement
Ethylenediaminetetraacetic acid (EDTA) plasma samples
for measurement of ADM were obtained at arrival in ED
and on the next 4 days during hospitalization. Aliquots
for ADM measurement were stored at −40°C and then
measured in a blinded fashion batch-wise using a recently
developed immunoassay [18]: The ADM assay is a one-step
sandwich-coated tube chemiluminescence immunoassay,
based on Acridinium NHS-ester labeling for the detection
of human ADM in unprocessed, neat plasma. It employs
two mouse monoclonal antibodies, one directed against
the mid region (solid phase), the other directed against the
amidated C-terminal moiety of ADM (labeled antibody).
Polystyrene tubes (Greiner Bio-One GmbH, Frickenhausen,
Germany) were coated with the anti-mid-regional antibody
(per tube 1.5 μg antibody in 300 μL of 50 mmol/L
Tris, 100 mmol/L NaCl, pH 7.8) overnight at 22°C. Tubeswere then blocked with 10 mmol/L Na-phosphate (pH 6.5)
containing 3% Karion FP (Merck KGaA, Darmstadt,
Germany) and 0.5% BSA (protease-free) and lyophilized.
The anti-C-terminal antibody (1 g/L) was labeled by incuba-
tion with MACN-acridinium-NHS (N-hydroxysuccini-
mide)-ester (1 g/L; InVent GmbH, Hennigsdorf, Germany)
in a 1:5 molar ratio for 20 minutes at 22°C. The reaction
was stopped by addition of 1/5 volume of 50 mmol/L gly-
cine for 10 minutes at 22°C. Labeled antibody was separated
from free label by size exclusion chromatography first on a
Centri Pure P5 Hydrated gel filtration column (emp Biotech
GmbH, Berlin, Germany) and followed by a Bio-SilectW Sec
 p<0.0001
Figure 1 Plasma Adrenomedullin (ADM) concentrations
depending on severity of disease. ADM concentrations are shown
for patients with sepsis and severe sepsis/septic shock on admission.
p<0.0001 
Figure 2 Association of Adrenomedullin (ADM) with
vasopressor treatment. ADM concentrations are shown for
patients who received (yes) or did not receive (no) vasopressor
treatment on admission.
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Germany) for HPLC. For the immunoassay the labeled anti-
body was diluted into assay buffer (300 mmol/L K-phos-
phate; 100 mmol/L NaCl; 10 mmol/L sodium EDTA; 5 g/L
BSA (protease-free) (Sigma); 1 g/L each of nonspecific bo-
vine and mouse IgG; 0.9 g/L Na-azide; 20 tabs/L Protease
Inhibitor Cocktail (Roche Diagnostics GmbH, Penzberg,
Germany); 10 μmol/L Amastatin; 20 μmol/L Leupeptin;
pH 7.0). Dilutions of full-length human ADM peptide
(American Peptide Company, Sunnyvale, CA, USA) in Cali-
brator Dilution Buffer (10 mmol/L Tris; 250 mmol/L NaCl;
2 g/L Triton X-100; 50 g/L BSA (protease-free); 20 tabs/L
Protease Inhibitor Cocktail (Roche AG); pH 7.0) served as
calibrators. The immunoassay was performed as follows:
50 μL of plasma samples/calibrators and 200 μL of labeled
detection antibody (800,000 relative light units (RLU) per
200 μL) were pipetted in the coated tubes. The assay was
incubated for 18 hours at 4°C. Unbound tracer was re-
moved by washing five times with wash solution (1 mL
each). Tube-bound chemiluminescence was measured for
1 s using the LB953 Multi-Tube Luminometer (BERT-
HOLD TECHNOLOGIES GmbH & Co. KG, Bad Wildbad,
Germany). The analytical assay sensitivity was 2 pg/mL. The
median ADM concentration of 200 healthy subjects was
20.7 pg/mL; the 99th percentile was 43 pg/mL. The ADM
sandwich assay used is not commercially available, but has
been provided for research purposes by Sphingotec GmbH.
MR-proADM measurement
Admission EDTA plasma samples, which were available
from 65 patients, were measured in the BRAHMS MR-
proADM KRYPTOR immunoassay (Thermo Fisher Scien-
tific, Hennigsdorf, Germany) according to the instructions
of the manufacturer.
Statistical analysis
Values are expressed as mean and standard deviation,
median and IQR, or count and percentage as appropri-
ate. The nonparametric Spearman correlation coefficient
is given to describe the association between continuous
variables. Group comparisons were performed using non-
parametric tests (Kruskal-Wallis test for continuous vari-
ables and chi-square (χ2) test with simulated P-values
using 2,000 replicates for categorical data). Biomarker data
were log-transformed. To analyze the effect of individual
risk factors on survival, univariable Cox proportional-
hazards regression was calculated. The assumption of pro-
portional hazard was tested for all variables. Log-
transformed values of ADM and the APACHE score were
evaluated in a multivariable Cox regression model to
evaluate the contribution of ADM over and above that of
APACHE alone based on nested models. The predictive
value of each model was assessed by the model likelihood
ratio chi-square statistic. The concordance index (C index)is given as an effect measure. Survival curves plotted by
the Kaplan-Meier method were used for illustration. All
statistical tests were two-tailed and a two-sided P-value
of 0.05 was considered significant. The statistical ana-
lyses were performed using R version 2.5.1.Results
At the time of admission, ADM concentrations were
associated with the severity of disease: ADM was
Table 2 Association of several variables obtained on admission with 28-day mortality
Variable Died within 28 days (n = 29) Survived 28 days (n = 72) P-value
ADM, pg/mL, median (IQR) 83.8 (48.3 to 232) 50 (31.2 to 77) <0.001
PCT, ng/mL, median (IQR) 4.8 (1.4 to 13.9) 2.2 (0.6 to 8.9) 0.0523
Creatinine clearance, mL/minute, median (IQR) 31.5 (16 to 68) 56 (28 to 81) 0.0539
Creatinine, mg/dL, median (IQR) 1.8 (1 to 3.1) 1.25 (0.9 to 2.1) 0.0922
CRP, mg/dL, median (IQR) 17.4 (6.8 to 26.9) 14.5 (6.4 to 23.5) 0.7114
White cells, 109 cells/L, median (IQR) 11.0 (26.5 to 17.2) 13.3 (8.1 to 17.7) 0.2416
Platelets, 109 cells/L, median (IQR) 185 (127 to 237) 217 (162 to 299) 0.0979
APACHE II score, points, median (IQR) 22 (18 to 27) 14 (12 to 18) <0.001
ADM, Adrenomedullin; PCT, Procalcitonin; CRP, C-reactive protein; APACHE II, acute physiology and chronic health evaluation II.
Figure 3 Association of Adrenomedullin (ADM) with cause of
death. Admission ADM concentrations are shown for patients
depending on their intra-hospital cause of death.
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and were significantly (P <0.001) higher in patients pre-
senting with severe sepsis or septic shock (93 (50 to 232)
pg/mL) compared to those with sepsis only (48 (32 to 72)
pg/mL, P <0.0001) (Figure 1).
Admission ADM levels were negatively correlated with
mean arterial pressure (MAP) (r = −0.39; P <0.0001).
Patients who required vasopressors on admission had
significantly (P <0.0001) higher ADM concentrations
(129 (83 to 264) pg/mL) than those who did not require
vasopressors infusion (48 (32 to 75) pg/mL) (Figure 2).
There was a non-statistical trend toward higher ADM
levels on admission (87 (44 to 133) pg/mL) in the four
patients who later required vasopressor (87 (44 to 133)
pg/mL) compared with those patients who did not
receive vasopressor therapy during hospital stay (48 (32
to 72) pg/mL) (P = 0.448).
Over the observation period of 28 days following
admission, 29 of the 101 patients died (28%). These
patients had significantly higher admission ADM con-
centrations (84 (48 to 232) pg/mL) than the survivors
(50 (31 to 77) pg/mL) (P <0.001) (Table 2). Median
(IQR) of the APACHE II score was 22 (18 to 27) in
non-survivors and 14 (12 to 18) in survivors (P <0.001).
For the discrimination of survivors from non-survivors
PCT and creatinine clearance were borderline significant
(P = 0.0523 and P = 0.0539). Admission ADM levels were
higher in patients who died in the hospital due to septic
shock (177 (77 to 289) pg/mL) than in patients who died
in the hospital due to other causes (54 (45 to 96) pg/mL)
(P = 0.04) (Figure 3).
The standardized hazard ratio (HR) from the Cox re-
gression model of continuous ADM levels at admission
for predicting 28-day mortality was 2.6; (C index) area
under the curve (AUC) = 0.69; χ2 = 18.2; P <0.0001. For
the APACHE II score, the results from Cox regression
analysis were (C index) AUC = 0.75; χ2 = 22.2; P <0.0001).
ADM was independent from APACHE II and provided
additional prognostic information (added χ2 = 5.2; P = 0.02).
From a subset of 65 patients admission levels of MR-
proADM were available. In the Cox regression modelfor predicting 28-day mortality MR-proADM performed
worse ((C index) AUC = 0.60; χ2 = 1.46; P <0.22)) than
ADM ((C index) AUC = 0.74; χ2 = 13.9; P <0.00019)).
We further assessed whether additional serial measure-
ments of ADM in patients during their hospital stay would
improve the prognostic value of ADM measurement on
admission. The C index for predicting mortality continu-
ously increased, the later ADM was measured (Table 3,
P <0.01 for added value of ADM on days 3 and 4 on
top of ADM on admission). The potential value of serial
ADM measurement is illustrated in Figure 4: patients with
an ADM admission concentration of above 70 pg/mL had
a 28-day survival rate of 55%. For those patients from this
group whose ADM concentration had remained above
Table 3 Cox regression analysis for prediction of 28-day mortality
Variable χ2 P-value C index (AUC) P-value of added value on top of ADM on admission
ADM, admission 18.2 <0.0001 0.69 -
ADM, day 1 21.2 <0.0001 0.70 0.079
ADM, day 2 20.5 <0.0001 0.72 0.113
ADM, day 3 26.4 <0.0001 0.74 0.004
ADM, day 4 29.9 <0.0001 0.75 <0.001
If follow up data were missing, the last observation was carried forward. ADM, Adrenomedullin; AUC, area under the curve.
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survival rate was 36%. In contrast, when ADM levels
had decreased to concentrations below 70 pg/mL the
survival rate was 100%.
Discussion
Using a novel ADM sandwich immunoassay, which se-
lectively detects the bioactive C-terminally amidated
ADM variant, this study demonstrates that plasma ADM
levels in septic patients admitted to the ED increase with
the severity of disease, correlate with the requirement for
vasopressor therapy, and are associated with the 28-day
mortality rate similar to APACHE II.
Although plasma ADM levels have been previously
assessed in several small studies of septic patients [9,15-17],
the assays used required large sample volumes, sample
extraction, and long incubation times. Moreover, the
technical validity of these competitive radioimmunoassays
has been questioned [21]. Thus, there are restrictions with
interpreting the ADM data of these studies due to the
limited number of patients investigated and the type ofTime (days)
0 7 14 21 28
Figure 4 Illustration of added value of serial Adrenomedullin (ADM) m
with ADM values above or below 70 pg/mL on admission (left) and for the
spread into those with ADM values above or below 70 pg/mL 4 days laterADM assays used, and consequently, the true potential
clinical value of ADM measurement in septic patients
has been difficult to judge. Measurement of a stable
fragment of the ADM precursor peptide, namely MR-
proADM, has been introduced to circumvent some of
these existing problems [22-24]. However, conceptually,
using MR-proADM as a surrogate for ADM has limita-
tions: It does not reflect potential imbalances between
the non-functional glycine-extended and the bioactive
amidated ADM, and it must be assumed to have different
clearing kinetics to ADM.
In the present study we demonstrated a strong associ-
ation of admission ADM levels with the severity of the dis-
ease, supporting an earlier report describing elevated ADM
levels in those with severe sepsis and those with septic
shock [15]. It also supports several studies where MR-
proADM was used as surrogate marker for ADM [7,23].
It is interesting that although ADM is known to be a
potent vasodilator, in the present study it was negatively
correlated to MAP, with a strong association to the need
for vasopressor therapy. A correlation of plasma ADMTime (days)
0 7 14 21 28
easurement. Kaplan-Meier Plots for survival are shown for patients
subgroup of patients, who were above 70 pg/mL on admission and
(right).
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tone has been previously observed [17]. In our study, the
patients who only later developed the need for vasopressor
therapy actually had elevated ADM levels at admission.
Clearly, a larger study is needed to confirm that elevation
of ADM precedes the requirement for vasopressor therapy.
If confirmed, measurement of ADM could become a help-
ful additional tool to guide vasopressor therapy.
In one study investigating only 12 septic patients, admis-
sion ADM did not distinguish survivors from non-survivors
and did not correlate with mean arterial pressure [9]. Our
much larger study with a more robust assay demonstrates
that ADM levels on admission were strongly associated
with the 28-day mortality rate. In fact, ADM was superior
over PCT, creatinine clearance and, albeit tested only in a
subset of patients, MR-proADM. Admission ADM levels
were higher in those who died from septic shock in the
hospital compared to other causes of death.
Using Cox regression analysis we could demonstrate
that the accuracy for predicting mortality with plasma
ADM levels increases, the later the ADM measured is
made during the hospital stay. This indicates that serial
measurement of ADM may add important information
to admission levels and ADM might be suitable for therapy
monitoring of sepsis patients. We illustrated the potential
of monitoring using ADM by applying a cut off value of
70 pg/mL, which is close to the 99th percentile of the nor-
mal range (43 pg/mL): patients who were admitted with
ADM levels above 70 pg/mL had a 28-day survival rate
of 55%. For those patients from this group, whose ADM
levels dropped to levels below 70 pg/mL 4 days later, the
survival rate was 100%. The cut off was selected retrospect-
ively as an example for how to distinguish groups with dif-
ferent risks to experience an adverse outcome depending
on serial development of a biomarker concentration. The
optimal cut off needs to be validated in future studies.
Conclusions
In patients admitted to the ED with sepsis, severe sepsis,
or septic shock, plasma ADM assessment is strongly asso-
ciated with severity of disease, vasopressor requirement
and 28-day mortality. Further research is warranted to
assess in more depth the possible clinical utility of
ADM measurement in patients hospitalized with sepsis.
Key messages
 In sepsis patients admitted to the ED, mature plasma
(ADM) measured by a novel sandwich immunoassay,
is associated with severity of disease, 28-day mortality
rate (independent from and additive to APACHE II),
and requirement for vasopressor therapy.
 Serial measurement of ADM improves mortality
risk prediction.Abbreviations
ADM: Adrenomedullin; APACHE: II acute physiology and chronic health
evaluation II; BSA: bovine serum albumin; CRP: C-reactive protein; ED: Emergency
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